• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Neumentum raises $6m for non-opioid pain-killers

December 6, 2017 By Sarah Faulkner

NeumentumPalo Alto, Calif.-based pharma company Neumentum said today that it raised $6 million in a Series A round through the sale of convertible preferred stock.

The company plans to use its newly-acquired funds to advance two non-opioid drug products designed for pain management.

“People in pain – and the professionals who treat them – deserve pain treatment options that are safer and more effective than those widely available today,” president & CEO Scott Shively said in prepared remarks. “Our executive team has extensive drug development and commercial experience in the pain and neurology space. Securing our A-series round of capital, as well as meeting with the FDA, are key steps forward in our mission to create better options for pain management.”

Neumentum’s lead product candidates include NTM-001, a pre-mixed ketorolac formulation for continuous infusion, and NTM-002, an intravenous patient-controlled analgesia.

The company said it has requested a meeting with the FDA to discuss the Phase III program of NTM-001, a product which it hopes to bring to the post-surgical acute pain management market.

“Postsurgical and other acute pain syndromes can be severe. Evidence suggests that pain, even in the hospital setting, is not always treated effectively,” executive chairman Dr. Joseph Pergolizzi added. “The role of opioids in pain control has come under great scrutiny and not all patients are suitable candidates for opioid pain relievers. Neumentum is addressing a serious problem with under-treated postsurgical pain by providing a new non-opioid analgesic option. We are excited to create a company that will help to transform the future of pain management.”

Injectable ketorolac is frequently administered to patients with postsurgical pain, but it is only available as an intravenous bolus injection, according to Neumentum. The company reported that its ketorolac formulation maintains a smooth pharmacokinetic profile over 24 hours when continuously infused.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Featured, Funding Roundup, Pain Management, Pharmaceuticals Tagged With: neumentum

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS